Cell line · CVCL_0609
Papers122
1 to 20 of 122
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Searching for Novel COVID19 Treatments: Towards Covalent TMPRSS2 Inhibitors. | ChemMedChem | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Calu-3 cells as novel efficient cell culture system for Borna disease virus 1 (BoDV-1). | Virus Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Host cell entry and neutralisation sensitivity of H3N2 influenza A virus subclade K. | NPJ Vaccines | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The conserved QTQTX motif in the SARS-CoV-2 spike protein is dispensable for cleavage and lung cell entry of the emerging variant BA.3.2. | J Virol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Hypoxia-inducible Factor 1α-dependent Induction of Alveolar miR-147b and Direct Targeting of Viral RNA in SARS-CoV-2-associated Acute Respiratory Distress Syndrome. | Anesthesiology | 2026 | Its Methods give the RRID and name the line | PubMed | |
| miR-29a and miR-15b Modulate SARS-CoV-2 Beta and Omicron Infection in Human Lung Epithelial Cells. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Multi-Omics reveals SPP1 + malignant and CXCR4+ TAM crosstalk predicts immunotherapy response in lung adenocarcinoma. | Discov Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Q1020R in the spike proteins of MERS-CoV from Arabian camels confers resistance against soluble human DPP4. | J Virol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| AXL-SHC1 signaling axis mediates adaptive resistance to HER2-targeted tyrosine kinase inhibitors in HER2-aberrant lung and gastric cancers. | NPJ Precis Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting peptidyl-arginine deiminase 4 suppresses SARS-CoV-2 replication and modulates the inflammatory response. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti-PD-1 Therapy. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Assessment of SARS-CoV-2 immune escape using antigenic cartography combined with experimental challenge studies. | NPJ Vaccines | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Searching for Novel Antiviral Agents as COVID19 Treatments: Guanidino Diaryl Thioureas. | ChemMedChem | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Antitumor Activity of Trastuzumab Deruxtecan in Pediatric Solid Tumors with Variable HER2 Expression. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| HNRNPA2B1 confers immune escape of non-small cell lung cancer through targeting lactate/ferroptosis. | Cell Death Dis | 2025 | Its Methods give the RRID and name the line | PubMed | |
| HACD3 promotes malignant progression of NSCLC by suppressing the MKK7/MAPK10 signaling axis. | BMC Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of coronaviral exonuclease activity by TRIM-mediated SUMOylation. | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Mutation T9I in Envelope confers autophagy resistance to SARS-CoV-2 Omicron. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Entry Efficiency, Protease Dependence, and Antibody-Mediated Neutralization of SARS-CoV-2 Sublineages KP.3.1.1 and XEC. | Vaccines (Basel) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| A live attenuated SARS-CoV-2 vaccine constructed by dual inactivation of NSP16 and ORF3a. | EBioMedicine | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0609/papers